Invention Grant
- Patent Title: Integrin Antagonists
-
Application No.: US15109602Application Date: 2015-01-06
-
Publication No.: US10533044B2Publication Date: 2020-01-14
- Inventor: M. Amin Arnaout
- Applicant: The General Hospital Corporation
- Applicant Address: US MA Boston
- Assignee: The General Hospital Corporation
- Current Assignee: The General Hospital Corporation
- Current Assignee Address: US MA Boston
- Agency: Fish & Richardson P.C.
- International Application: PCT/US2015/010384 WO 20150106
- International Announcement: WO2015/103643 WO 20150709
- Main IPC: C07K14/78
- IPC: C07K14/78 ; C07K7/06 ; C07K7/08 ; C07K14/47 ; C07K7/64 ; A61K38/00

Abstract:
Provided herein are integrin antagonists and methods of using the same. For example, one or more of the compounds or polypeptides provided herein can be used in the treatment of disorders such as heart attacks, stroke, and cancer metastasis. Also provided herein is a crystal comprising αvβ3 ectodomain complexed with inhibitor knottin 2.5 F. Further provided herein is a crystal comprising αVβ3 ectodomain complexed with inhibitor hFN10. In another aspect, the invention features a method that includes using a three-dimensional model of a complex that includes an integrin ectodomain.
Public/Granted literature
- US20170044236A1 Integrin Antagonists Public/Granted day:2017-02-16
Information query